Shares of Zai Lab Ltd (NASDAQ:ZLAB) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation. Zai Lab’s rating score has improved by 50% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 12 month consensus target price of $38.50 for the company and are forecasting that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Zai Lab an industry rank of 184 out of 265 based on the ratings given to its competitors.
A number of equities research analysts have recently commented on ZLAB shares. BidaskClub raised shares of Zai Lab from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 10th. JPMorgan Chase & Co. raised shares of Zai Lab from a “neutral” rating to an “overweight” rating and set a $32.00 price objective on the stock in a research note on Wednesday, February 14th.
Zai Lab (NASDAQ ZLAB) traded up $0.76 during trading hours on Thursday, hitting $24.25. 104,104 shares of the stock were exchanged, compared to its average volume of 85,132. Zai Lab has a 12 month low of $19.80 and a 12 month high of $35.74.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2018/02/20/zacks-zai-lab-ltd-zlab-receives-consensus-recommendation-of-strong-buy-from-analysts.html.
About Zai Lab
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.